New cocktail aims to tackle tough liver cancer

NCT ID NCT07392866

Not yet recruiting Disease control Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of drugs (SH006 plus chemotherapy) against the standard drug regorafenib in 120 people with advanced liver cancer that has not responded to immunotherapy. The goal is to see if the new combo can slow cancer growth or improve survival. Participants will be randomly assigned to one of the two treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SH006 (a drug similar to bevacizumab) combined with oxaliplatin, capecitabine, and bevacizumab
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced liver cancer who have already tried immunotherapy.
What could go wrong: This is an early-to-mid stage trial with only 120 participants. The new combination may not be more effective than the existing drug regorafenib, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Nanjing Tianyinshan Hospital

Nanjing, Jiangsu, 211199, China
Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.